Advanced Medical Isotope (ADMD) Stock: RadioGelTM Moves A Step Forward


Advanced Medical Isotope Corp. (OTCMKTS: ADMD) released some big news yesterday! The company announced that it has had its first discussions with private animal consortiums to utilize RadioGelTM. This is a huge step in the right direction. Here’s what’s happening:

ADMD Holds First Talks With Private Animal Consortiums

As mentioned above, Advanced Medical Isotope made a major leap with an announcement yesterday surrounding their goal of bringing RadioGel to market for the treatment of skin cancer. The company announced yesterday that it has held its first discussions with private animal consortiums in order to prove safety and effectiveness of the product through testing at four university veterinary hospitals.

By taking advantage of access to private veterinary clinics, the company will be able to form business arrangements with large consortiums of private clinics in a cost-effective way. The company has had conversations with Veterinary Cancer Group and with VCA Inc. with the goal of gaining firsthand information on the steps required to market RadioGel in the commercial sector. With 55 veterinary centers that feed into 3 specialty clinics. VCA has 820 clinics in the United States and Canada with 25 specialty treatment centers.

According to the company’s press release, both consortiums have expressed a strong opinion with regard to the importance of learning from testing that the company is sponsoring at university veterinary centers. They have also encouraged ADMD to publish the results in a scientific journal. In fact, VCG expressed interest in teaming up with the universities by conducting some of the testing within their own facilities.

With such interest in the veterinary space, ADMD will likely have all it needs in order to move through the non-human testing phase surrounding this potentially game-changing treatment. Ultimately, this brings them one step closer to testing in humans, and their ultimate goal of bringing the treatment to the regulatory approval under the skin cancer indication.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on ADMD. I particular, we’re interested in following the ongoing efforts surrounding RadioGel and excited to see where this treatment goes as it continues through development. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required


Please enter your comment!
Please enter your name here